Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat

Posted: October 21, 2022 at 2:22 am

EDISON, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other fibrotic diseases, today announced that the peer-reviewed journal, Clinical Pharmacology in Drug Development, has published the results of a clinical trial examining the effect of food on the oral bioavailability of rencofilstat, the Company’s lead drug candidate.

More here:
Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat

Related Posts